Log in
Lost password
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Tokyo  >  DAIICHI SANKYO COMPANY, LIMITED    4568   JP3475350009

News SummaryMost relevantAll newsSector news 

DAIICHI S : Notice on Details of the Share Options

07/12/2011 | 04:20am US/Eastern
For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Joji Nakayama, President and CEO

(Code no.: 4568, First Section of Tokyo, Osaka and Nagoya Stock Exchanges) Please address inquiries to Toshiaki Sai, Corporate Officer, Vice President, Corporate Communications Department

Telephone: +81-3-6225-1126

http://www.daiichisankyo.com/Notice on Details of the Share OptionsTOKYO, Japan (July 12, 2011) Daiichi Sankyo Company, Limited has announced that the subscription amount and other details of its No.5 share options were decided today. As previously announced, the Board of Directors had reached a decision on June 27, 2011 to issue the said share remuneration-type stock options (share options) to remunerate Directors (excluding Outside Directors) and Corporate Officers

1. Name of share options

Daiichi Sankyo Company, Limited No. 5 share options

2. Total number of share options

2,328 share options (100 shares per one share option) Breakdown

Six (6) Directors: 1,102 share options

Eighteen (18) Corporate Officers: 1,226 share options

3. Subscription amount for share options

111,200 yen per share option

(1,112 yen per share)


Date of Board of Directors resolution: June 27, 2011

React to this article
02/04 DAIICHI SANKYO : New Investigative Ophthalmology and Visual Science Data Have Be..
02/04 DAIICHI SANKYO : Findings from Daiichi Sankyo Broaden Understanding of Applied T..
02/02 DAIICHI SANKYO : expands access to its clinical trial data
02/01 DAIICHI SANKYO : to Expand Access to Clinical Trial Data
01/28 DAIICHI SANKYO : Selected for RobecoSAM Industry Mover Sustainability Award 2016
01/23 SMi Group reports registration now open for the 10th annual Clinical Trial Lo..
01/22 SMi Group reports registration now open for the 10th annual Clinical Trial Lo..
01/14 DAIICHI SANKYO : New Stem Cell Research Study Findings Have Been Reported by Inv..
01/11 DAIICHI SANKYO : Announces Results of Phase 3 International Joint Trial (RApsody..
01/11 DAIICHI SANKYO : Announces Change in Corporate Officer's Responsibilities
News chart
Full-screen chart
Income Statement Evolution
More Financials